Saari, Eeva
Mononen, Minna
Hasala, Hannele
Lätti, Anne
Kaulamo, Johanna
Nurmi, Hanna
Kaarteenaho, Riitta
Purokivi, Minna
Koskela, Heikki O
Article History
Received: 16 December 2022
Accepted: 10 May 2023
First Online: 23 May 2023
Declarations
:
: The study protocols were approved by the Research Ethics Committee of the Northern Savo Hospital district (statement 80/2014), Research Ethics Committee of the Northern Savo Hospital district (statement 289/2015), and Tampere University Hospital (R15149). The studies were conducted in compliance with the Declaration of Helsinki (as revised in 2013). A written informed consent was obtained or response to an electronic questionnaire was considered to be informed consent.
: Not applicable
: ES: personal consulting fee and congress travel costs from Boehringer Ingelheim, congress travel costs from Novartis Finland, Orion Pharma, AstraZeneca, virtual congress costs from Roche, owns personal stocks from Orion Pharma LTD, Board member of Finnish allergology- and immunology association, outside the submitted work. MM: personal consulting fee, congress travel costs and a lecture fee from Boehringer Ingelheim, outside the submitted work. AL: personal congress travel costs from Boehringer Ingelheim, Novartis, lecture fees from the Pharmaceutical Learning Centre, GlaxoSmithKline, Chiesi, MSD, Hengitysliitto, outside the submitted work, JK: personal congress travel costs from Boehringer Ingelheim outside the submitted work. HN: personal lecture fees from Boehringer Ingelheim and Roche, congress travel costs from Boehringer Ingelheim, Sanofi-Genzyme, and Chiesi, outside the submitted work. RK: personal consulting, lecture, and advisory board fees from Boehringer Ingelheim, a lecture fee from Roche, virtual congress costs from Roche, Novartis, an advisory board fee from MSD, outside the submitted work. MP: personal lecture fee, congress travel costs and advisory board member Boehringer Ingelheim, lecture fee Roche, congress travel costs Orion Pharma, outside the submitted work. HOK: personal lecture fee from Boehringer Ingelheim, personal congress travel costs from AstraZeneca, owns personal stocks from Orion Pharma LTD, outside the submitted work. HH declares no competing interests.